Siemens Healthineers Considers Strategic Divestment of Diagnostics Unit
Published on 04/07/2026 at 05:46 | Redaktion boerse-global.de
Siemens Healthineers is conducting a strategic review of its Diagnostics division, with a potential separation now on the table. In a significant admission, Chief Executive Bernd Montag stated the company may no longer be the optimal owner for this business segment, signaling a potential acceleration of the ongoing corporate restructuring.
Financial Performance Highlights Diverging Paths
The latest financial results underscore the rationale behind the strategic shift. While the group's total revenue increased by 3.8 percent, the Diagnostics unit is acting as a drag on overall performance. This segment is reducing the group's total growth by approximately one percentage point and pressuring margins by two percentage points. For the first quarter of fiscal 2026, Diagnostics contracted by three percent. This decline occurred as the Imaging and Advanced Therapies divisions served as the company's primary growth engines.
Despite these operational headwinds, the adjusted earnings per share fell three percent to €0.49. The company's leadership has identified pricing pressure from a Chinese procurement program as a major challenge for the current quarter, a point emphasized by CFO Jochen Schmitz.
Should investors sell immediately? Or is it worth buying Siemens Healthineers?
The Growth Gap and Operational Independence
Looking ahead to fiscal 2027, the divergence between business units becomes even more pronounced. Management projections indicate the Diagnostics division is expected to deliver only mid-single-digit revenue growth. In contrast, the combined Imaging and Precision Therapy businesses have the potential to grow by up to nine percent.
Company executives note that these two core areas already function largely as independent entities. Therefore, a formal separation is unlikely to create significant operational friction or efficiency losses. For the overall group, Siemens Healthineers is targeting annual revenue growth of five to seven percent between 2027 and 2030, accompanied by double-digit growth in adjusted earnings per share.
Upcoming Quarterly Report to Provide Crucial Insights
Despite the pressures, the company has reaffirmed its full-year outlook. It anticipates comparable revenue growth of five to six percent, with adjusted earnings per share projected between €2.20 and €2.40. The upcoming quarterly report on May 7th is viewed as a critical milestone for investors. It is expected to reveal whether business in China shows signs of stabilization in the second quarter and to outline any concrete steps resulting from the Diagnostics strategic review. This report will serve as a key test of whether the company's bifurcated operational performance begins to converge or becomes further entrenched.
Ad
Siemens Healthineers Stock: New Analysis - 7 April
Fresh Siemens Healthineers information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
